Baxter International Inc. (BVMF:B1AX34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 73.36B +48.3% |
| Revenue (ttm) | 60.14B +5.3% |
| Net Income | -3.75B |
| EPS | -3.87 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 12.57 |
| Dividend | 0.07 (0.10%) |
| Ex-Dividend Date | Nov 26, 2026 |
| Volume | 2 |
| Open | 71.02 |
| Previous Close | 73.15 |
| Day's Range | 71.02 - 71.02 |
| 52-Week Range | 40.97 - 73.27 |
| Beta | 0.67 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Baxter International
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies;... [Read more]
Financial Performance
In 2025, Baxter International's revenue was $11.24 billion, an increase of 5.72% compared to the previous year's $10.64 billion. Losses were -$957.00 million, 47.5% more than in 2024.
Financial numbers in USD Financial StatementsNews
Baxter price target raised to $23 from $20 at Barclays
Barclays raised the firm’s price target on Baxter (BAX) to $23 from $20 and keeps an Underweight rating on the shares.
Baxter price target lowered to $25 from $26 at JPMorgan
JPMorgan lowered the firm’s price target on Baxter (BAX) to $25 from $26 and keeps a Neutral rating on the shares.
Baxter price target lowered to $25 from $28 at Stifel
Stifel analyst Rick Wise lowered the firm’s price target on Baxter (BAX) to $25 from $28 and keeps a Hold rating on the shares.
Baxter price target lowered to $25 from $27 at Jefferies
Jefferies lowered the firm’s price target on Baxter (BAX) to $25 from $27 and keeps a Hold rating on the shares. Baxter has put up two “solid quarters in a…
Baxter International Earnings Call Transcript: Q3 2026
Q3 sales rose 5% organically and adjusted EPS was $0.58; free cash flow reached $448M. FY26 organic growth and adjusted EPS guidance rose, while deleveraging and quality remediation remain priorities.
Baxter International Earnings release: Q3 2026
Baxter International released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Baxter International Slides: Q3 2026
Baxter International has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Baxter International Quarterly report: Q3 2026
Baxter International has published its Q3 2026 quarterly earnings report on October 29, 2026.
Baxter Reports Third-Quarter 2026 Results
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2026. “We delivered a strong third quarter, with growth...
Site inspection warning letter sent to Baxter posted to site of FDA
The FDA posted a warning letter that the agency sent to Baxter (BAX) International, dated September 29, that states in part: “This warning letter advises you of significant violations observed…
Baxter to Host Third-Quarter 2026 Financial Results Conference Call for Investors
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2026 financial results on Thursday, October 29...
Baxter initiated with an Underweight at Barclays
Barclays initiated coverage of Baxter (BAX) with an Underweight rating and $20 price target The firm rolled out coverage of the medical suppliers and devices group with a Positive rating.
Baxter price target lowered to $27 from $28 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on Baxter (BAX) to $27 from $28 and keeps a Neutral rating on the shares. The firm adjusted targets in the…
Baxter Releases Inaugural Connected Hospital Report
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the release of its 2026 Connected Hospital Report, offering new insights into how hospi...
Baxter International Transcript: Wells Fargo 21st Annual Healthcare Conference
Decentralization, continuous improvement, and debt reduction are driving operational and financial progress, with new leadership and product innovation supporting future growth. Business segments show mixed performance, but stability and targeted investments position the company for long-term value creation.
Baxter appoints Rogers as Chief Financial Officer
Baxter (BAX) International announced it has appointed John Rogers as executive vice president and chief financial officer, CFO, reporting to Baxter president and chief executive officer, CEO, Andrew H...
Baxter Appoints John Rogers Chief Financial Officer
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed John Rogers as executive vice president and chief financial officer (C...
Baxter Announces Pricing for Its Upsized Cash Tender Offers
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced the pricing terms for its previously announced cash tender offers (each, an “Offer” a...
Baxter Announces Early Tender Results and Upsizing of Previously Announced Cash Tender Offers
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced the early results of its previously announced cash tender offers (each, an “Offer” an...
Baxter announces cash tender offers
Baxter (BAX) International has commenced cash tender offers for the maximum principal amount of validly tendered notes set forth, such that the aggregate purchase price, not including accrued and unpa...
Baxter Announces Cash Tender Offers
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced that it has commenced cash tender offers (each, an “Offer” and collectively, the “Off...
Baxter price target raised to $28 from $24 at BofA
BofA analyst Travis Steed raised the firm’s price target on Baxter (BAX) to $28 from $24 and keeps a Neutral rating on the shares. With the multiple having expanded, the…
Baxter price target raised to $29 from $24 at TD Cowen
TD Cowen raised the firm’s price target on Baxter (BAX) to $29 from $24 and keeps a Hold rating on the shares. The firm said they posted a solid quarter…
Baxter price target raised to $27 from $20 at Deutsche Bank
Deutsche Bank analyst Pito Chickering raised the firm’s price target on Baxter (BAX) to $27 from $20 and keeps a Hold rating on the shares.
Baxter price target raised to $28 from $24 at Stifel
Stifel raised the firm’s price target on Baxter (BAX) to $28 from $24 and keeps a Hold rating on the shares.